Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (72)

Latest Posts

About This Stock More About This Stock
Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak
Article By: Zacks Investment Research
Thursday, November 2, 2017 11:52 AM EST
Sanofi reported third-quarter 2017 earnings of $1.00 per American depositary share, which were in line with the Zacks Consensus Estimate. Earnings declined 4.5% on a reported basis.
In this article: SNY Also: MRK, REGN, AMGN
Read
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EST
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EST
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read
Forget Teva, Buy These 4 Drug Stocks Instead
Article By: Arpita Dutt
Friday, August 11, 2017 1:17 PM EST
It’s not been a good quarter for Israel-based generic drug maker, Teva Pharmaceutical Industries Limited. Teva missed on both second quarter earnings and revenues and lowered its outlook for 2017.
In this article: SNY, ALXN, REGN, GILD, TEVA
Read
Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
Article By: Zacks Investment Research
Thursday, July 27, 2017 10:00 AM EST
Bayer AG’s second-quarter 2017 core earnings per share from continuing operations was $1.99. Earnings were down 12.7% year over year from $2.28 per share.
In this article: ENZ, MON, SNY, BAYRY
Read

PARTNER HEADLINES

Latest Tweets for $SNY

No tweets yet!